New York, NY, United States of America

Gregory Martin Sullivan

This inventor holds 0 USPTO granted patents, plus 2 CIPO patents and 2 EPO patents.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Gregory Martin Sullivan. Retrieved from https://idiyas.com/inventor/gregory-martin-sullivan

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


 

Average Co-Inventor Count = 1.0

ph-index = 1


Loading Chart...
Loading Chart...

Title: Gregory Martin Sullivan: Innovator in Neurocognitive Treatment

Introduction

Gregory Martin Sullivan is an inventor based in New York, NY (US). He has made significant contributions to the field of neurocognitive treatment, particularly through his innovative methods aimed at addressing cognitive impairments.

Latest Patents

Sullivan's notable patent is titled "Method For Treating Neurocognitive Dysfunction." This method involves administering an effective amount of at least one compound of a specific formula to treat corticosteroid-induced cognitive impairment. The formula includes various components that are carefully selected to optimize treatment efficacy.

Career Highlights

Throughout his career, Gregory Martin Sullivan has worked with several companies, including Tonix Pharma Holdings Limited and Tonix Pharmaceuticals Inc. His experience in these organizations has allowed him to develop and refine his innovative approaches to neurocognitive dysfunction.

Collaborations

[This section has been skipped.]

Conclusion

Gregory Martin Sullivan's work in neurocognitive treatment showcases his dedication to improving cognitive health through innovative methods. His contributions are significant in the ongoing quest to address cognitive impairments effectively.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…